RESET: A device for type 2 diabetes patients

The medical device industry is undergoing rapid change, driven by advances in digital health, biomaterials, and minimally invasive procedures that are redefining how chronic diseases are treated. Today’s innovators are increasingly focused on solutions that bridge the gap between traditional surgery and pharmaceutical therapy—approaches that deliver meaningful outcomes with less risk, recovery time, and cost. One example of this evolution is Morphic Medical’s RESET device, a new endoscopic technology designed to provide a non-surgical option for patients struggling with metabolic disorders such as obesity and type 2 diabetes.

The RESET system reflects a growing trend toward device-based metabolic interventions, which aim to alter physiological pathways through mechanical means rather than drugs or incisions. These technologies seek to harness the body’s own metabolic mechanisms, offering durable improvements in weight and glucose control without permanent alteration of anatomy. For patients who have not achieved sufficient results through medication or lifestyle changes—but are hesitant to pursue surgery—such devices may represent a new middle ground in care.

At the same time, regulators and clinicians are closely evaluating how these emerging tools fit within broader treatment frameworks. Questions about long-term efficacy, safety, and integration with drug therapies are central to determining their role in chronic disease management. The demand for scalable, cost-effective interventions continues to grow as obesity and diabetes rates climb worldwide, placing pressure on health care systems and expanding opportunities for new technologies.

Against this backdrop, Morphic Medical’s approach exemplifies the convergence of engineering innovation and metabolic science. In a conversation with Mike Gutteridge, the company’s chief executive officer, Medical Economics discussed how Morphic aims to redefine patient care through device-based therapies and how these developments reflect larger shifts shaping the future of the medtech industry.